Gene Therapy Market Report (2022 to 2030) – Novartis AG, Spark Therapeutics Inc. (Roche), Gilead Sciences Inc., Biogen Inc., Avita Medical, Jazz Pharmaceuticals Plc. and Celgene Corporation

20 Maxwell House, Singapore, Jan. 25, 2023 (GLOBE NEWSWIRE) — According to the latest report published by Growth Plus Reports, the global gene therapy market is expected to clock US$ 4.64 billion by 2030 and to grow at a CAGR of 8.1% during the forecast period. Gene therapy focuses on cell reprogramming to provide a novel remedy/treatment method for a disease by replacing the damaged gene. This sort of treatment shows promising outcomes for a variety of diseases or disorders, including heart disease, hemophilia/acquired hemophilia, cancer, and many more. Gene therapy has several uses, the most important of which is the development of vaccines for various infectious or chronic illnesses. This exclusive information is published by Growth Plus Reports in its report titled “Gene Therapy Market – Global Outlook & Forecast 2022-2030”

Get a Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/gene-therapy-market/8079

Market Drivers

The market’s expansion can be attributed to the rising prevalence of chronic diseases such as cancer, central nervous system disease, metabolic disorders, cardiovascular disease, and so on. Additionally, the growing R&D activity has resulted in the continuously increasing introduction of innovative products/therapies and the enhancement of the product pipeline. Furthermore, rising financings such as IPOs (initial public offerings), venture capital financing, follow-on financing, and expanding partnerships and acquisitions significantly influence market growth. For instance, in 2022, Bayer AG and Mammoth Biosciences Inc. announced a strategic collaboration for the development of novel in-vivo gene editing technology. Bayer’s gene therapy platform is strengthened further and Mammoth’s vision of unlocking the full potential of novel CRISPR systems is also being supported. Additionally, Mammoth is expected to receive an upfront payment of USD 40 million, with potential future payments of more than a billion USD upon successful achievement.

The gene therapy market has been analyzed from four perspectives: vector type, delivery type, application, end-users, and region.

Excerpts from ‘By Vector Type Segmentation’

The vector type in the global gene therapy market has been bifurcated into:

Non-viral vector has the largest revenue share in the market as this is a safer treatment approach with a cheap cost, making it accessible to those with limited financial resources. This segment also possesses a high gene capacity, a low immunogenic response, a high transfection efficiency, and the ability to be chemically adaptable. Furthermore, rising cancer and other targeted illness cases and increased funding in gene therapy also contribute to the growth of this segment, thereby propelling the gene therapy market. While viral vectors are the most effective in gene therapy, they offer limited applications as a result of the limitation of chemical flexibility, thus depicting a steady growth during the projected timeline.

Excerpts from ‘By Region Segmentation’

Geographically, the global gene therapy market has been segmented into:

• North America
• Europe
• Asia Pacific
• Rest of the World

North America holds the largest revenue share in the market. Growth in R&D activities to develop and deploy sophisticated and new medicines and/or products, hence increasing the product pipeline, aids in the development of the markets in this region. Additionally, increased government investment and a rise in funding by competitive market players benefit this regional market. Furthermore, enhanced healthcare infrastructure, substantial healthcare expenditures, and the presence of prominent market competitors all contribute to North America’s market development. The rapid adoption of modern technologies and an increase in chronic illness occurrences are major reasons for the market growth in Europe, making it the second-largest stakeholder in the global gene therapy market.

The Asia Pacific market is rapidly rising due to a large aging population base, a quickly changing healthcare sector, and the increasing adoption of novel technologies. Furthermore, the growing prevalence of various chronic diseases such as cancer, neurological diseases, cardiovascular diseases, and so on further contributes to the growth of the gene therapy market in this region.

Browse the full report with detailed TOC at:  https://www.growthplusreports.com/report/gene-therapy-market/8079

Excerpts from ‘Competitive Landscape’

Some prominent players operating in the global gene therapy market are:

• Novartis AG
• Biogen Inc.
• Spark Therapeutics Inc. (Roche)
• Gilead Sciences Inc.
• AGC Biologics (AGC Inc.)
• Orchard Therapeutics Plc.
• Dynavax Technologies
• Amgen Inc.
• Sibiono Genetech Co. Ltd.
• Sarepta Therapeutics
• Avita Medical
• Bluebird Bio Inc.
• Jazz Pharmaceuticals Plc.
• Celgene Corporation
• Mustang Bio

Table of Content

1. INTRODUCTION
   1. Market Ecosystem 
   2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecasted Years – 2022 to 2030
   3. Currency Used in the Report
2. RESEARCH METHODOLOGY 
   1. Research Approach
   2. Data Collection Methodology
   3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
   4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
   5. Market Forecasting Model
   6. Limitations and Assumptions       
3. PREMIUM INSIGHTS
   1. Current Market Trend (COVID-19 Perspective)
   2. Key Players & Competitive Positioning (2021)
4. MARKET DYNAMICS
   1. Drivers
   2. Restraints
   3. Opportunities
5. GLOBAL GENE THERAPY MARKET- ANALYSIS & FORECAST, BY VECTOR TYPE
   1. Viral
   2. Non-Viral

TOC Continued…

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• ‘Business Profile’ of Key Players

Inquiry Before Buying: https://www.growthplusreports.com/inquiry/before-buying/gene-therapy-market/8079

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.